Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.59 |
| ▸ | SMO | Q99835 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486377 | 0.92 | MAPK14 (0.63) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL7805580 | 0.86 | MAPK14 (0.56) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6487036 | 0.83 | MAPK14 (0.66) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6476182 | 0.82 | MAPK14 (0.69) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6969088 | 0.82 | MAPK14 (0.61) | MAPK14SMO | |
| SCHEMBL6476015 | 0.81 | MAPK14 (0.65) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6485519 | 0.80 | MAPK14 (0.89) | MAPK14SMOMEN1KMT2A | |
| SCHEMBL6782804 | 0.80 | MAPK14 (0.73) | MAPK14SMONPC1RAB9A | |
| SCHEMBL7107912 | 0.79 | MAPK14 (0.64) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6476455 | 0.78 | OPRK1 (0.61) | MAPK14SMOOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | MAPK14 2054/4885SMO 4147/4885OPRK1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.